• Product
  • Supplier
  • Inquiry


    Home > Chemial News > Company News > Counting the R&D investment of international pharmaceutical giants

    Counting the R&D investment of international pharmaceutical giants

    Echemi 2020-07-14

    In 2019, the US FDA approved a total of 48 new drugs, including Johnson & Johnson’s original anti-depression combination drug esketamine (Spravato) and Seragon Pharmaceuticals (Seragon Pharmaceuticals) originally developed adenocarcinoma drug ARN-509 (by Johnson & Johnson named it "Erleada" after the acquisition of US$1 billion). It was approved for listing this year, and in 2014, Tecentriq, a PD-L1 inhibitor of Roche, which received Sanogen’s revenue, was also obtained in 2019. Important progress.

    The major international pharmaceutical giants invested huge amounts of research and development funds last year to find and develop new drugs. What is different from previous years is that, except for Roche, Johnson & Johnson, Merck, and other giants, the situation is still strong. Pharmaceutical companies have also begun to enter new areas.

    Roche's R&D investment last year reached 12.31 billion US dollars, accounting for 19% of total revenue

    As we all know, cancer drugs have always been Roche's main source of revenue. Roche's R&D investment in 2019 is as high as 12.31 billion US dollars, which is 19.0% of its total revenue.



    This is because its three major sales champions Avastin, Merlot and Herceptin are about to lose patent protection, so it is understandable to increase the research and development efforts and expand the drug pipeline to make up for the market share that will be seized by biosimilars.

    In 2014, Roche acquired alternative treatments for breast cancer through the acquisition of Seragon Pharmaceuticals. Aragon, the predecessor of Sanogen, once focused on prostate cancer therapy and successfully developed Erleada, which was approved for listing last year. After that, the pharmaceutical companies acquired by Roche were all based on the development of cancer drugs. In 2019, Roche ushered in its technological turning point-the acquisition of AAV gene therapy well-known drug company Spark Therapeutics, expanding the hemophilia drug pipeline.

    Johnson & Johnson’s R&D budget last year was US$11.36 billion, accounting for nearly 14% of total revenue

    Although Johnson & Johnson's business scope is wide, it is not inferior in R&D investment. In 2019, Johnson & Johnson's R&D budget is US$11.36 billion, accounting for 13.8% of its total revenue.



    In March 2019, the FDA approved Johnson & Johnson’s esketamine (Spravato) in combination with oral antidepressants for anti-therapeutic depression in adults. Its treatment of patients with locally advanced or metastatic urethral epithelial cancer, eratinib (BALVERSA), has also become the world's first FGFR kinase inhibitor drug approved by the US FDA.

    Merck's R&D investment last year was 9.87 billion US dollars, accounting for more than 21% of revenue

    Merck's R&D investment ranks third among global pharmaceutical companies, with a total value of 9.87 billion US dollars, accounting for nearly 21.1% of its total revenue.




    In December 2019, the FDA approved the first Ebola virus (EVD) vaccine. Ebola has brought near-destructive blows to parts of sub-Saharan Africa, and the timely approval of this vaccine from Merck will help control its spread to other regions. Throughout 2019, Merck’s anti-cancer drug PD-1 inhibitor Keytruda received a total of 6 separate approvals from the FDA [7]. Merck’s invested a lot of money in the study of the drug for other cancers, and the gains were The biggest performance growth "engine".

    Judging from the research and development plans of Roche (including Sanogen Pharmaceuticals, Xinghuo Treatment), Johnson & Johnson and Merck, oncology treatments (especially clinical trials) are still the areas with the largest investment costs. Of course, from the perspective of the FDA's approval strategy and the high premium price of anticancer drugs, the investment and return of these large pharmaceutical companies are all directly proportional.

    Share to:
    Disclaimer: Echemi reserves the right of final explanation and revision for all the information.

    Scan the QR Code to Share

    Send Message